GHRH receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
SJIA is diagnosed clinically and corroborated by typical test findings; it is a diagnosis of exclusion. A child suspected of having sJIA should undergo a full evaluation for infection and cancer, including blood and urine cultures, imaging tests, and bone marrow exams to rule out leukemia or lymphoma. The International League of Associations for Rheumatology criteria for sJIA include arthritis, ≥2 weeks of daily fever, and symptoms like organomegaly, lymphadenopathy, serositis, or non-fixed/evanescent rash. Laboratory abnormalities are typical, but no specific tests are available for sJIA. Treatment for a disease varies greatly, requiring consideration of involvement, systemic characteristics, and MAS presence. Nonsteroidal anti-inflammatory medications can be safely administered for analgesic and antipyretic effects without altering initial diagnostic assessment results. Clinical trials show that anti-interleukin-6 and anti-interleukin-1 drugs are effective in managing systemic symptoms. Studies show that 40% of children with SJIA have a monocyclic disease history, recovering after varying periods. A small percentage experience a polycyclic course, with over half having a prolonged disease course. Juvenile idiopathic arthritis (JIA) is the most prevalent rheumatic illness in children, affecting 1 to 4 out of every 1000. SJIA accounts for 10% to 20% of cases, with peak presentation between 1 and 5 years. Children of all genders and ethnic origins are equally affected.
== Cast == Joseph Wairimu as Mwas Olwenya Maina as Oti Nancy Wanjiku Karanja as Amina Mugambi Nthiga as Cedric Paul Ogola as Mose Antony Ndung'u as Waf Johnson Gitau Chege as Kyalo Kamau Ndungu as John Waya Abubakar Mwenda as Dingo Mburu Kimani as Daddy M Mehul Savani as Khanji Maina Joseph as Kimachia Shix Kapienga Jacky Vike as Ruth
A radioimmunoassay (RIA) is an immunoassay that uses radiolabeled molecules in a stepwise formation of immune complexes. A RIA is a very sensitive in vitro assay technique used to measure concentrations of substances, usually measuring antigen concentrations (for example, hormone levels in blood) by use of antibodies. The RIA technique is extremely sensitive and extremely specific, and although it requires specialized equipment, it remains among the least expensive methods to perform such measurements. It requires special precautions and licensing, since radioactive substances are used. In contrast, an immunoradiometric assay (IRMA) is an immunoassay that uses radiolabeled molecules but in an immediate rather than stepwise way. A radioallergosorbent test (RAST) is an example of radioimmunoassay. It is used to detect the causative allergen for an allergy.
Hans Studener (1966–1969) Kurt Holke (1969–1971) Horst Scherbaum (1971–1976) Manfred Pfeifer (1976–1978) Heinz Joerk (1978–1979) Harro Miller (1979–1985) Hans-Ulrich "Uli" Thomale (1985 – February 1990) Gunter Böhme (February 1990 – 27 May 1991) VfB Leipzig
Sources: en.wikipedia.org
== Impact == Following the release of The Beauty, renewed interest emerged in the original comic, The Beauty #1, published by Image Comics. The issue appeared on Key Collector Comics' "Trending 20" list and was featured by the YouTube channel ComicTom101 in its "Hot 10" rankings over multiple consecutive weeks. Secondary market activity increased, with raw copies reportedly selling for as much as $64 on eBay, while higher-grade and later printings recorded correspondingly higher prices. During the week of the series' premiere, The Beauty #1 placed No. 7 among trending comics in the United States and was reported to have reached a sale price of $199 for a CGC 9.8 copy, with a near-mint fair market value of $53 for raw copies.
== O == octreotide - odorant receptor - olfaction - olfactory receptor neuron - oligopeptide - oncogene - oncogene protein - oncogene proteins V-abl - oncogenic retroviridae protein - open reading frame - opioid receptor - opsin - optical isomerism - organ (anatomy) - organelle - organic chemistry - organic compound - organic nomenclature - organic reaction - organism - osmosis - osteocalcin - outer hair cell - outline of biochemical techniques - ovalbumin - oxidation - oxidation number - oxidation state - oxidative decarboxylation - oxidative phosphorylation - oxygen - oxytocin - oxytocin receptor
Dark chocolate, 70–85% cocoa solids: 80 mg Dark chocolate, 60–69% cocoa solids: 86 mg Dark chocolate, 45–59% cocoa solids: 43 mg Milk chocolate: 20 mg The stimulant effect of chocolate may be due to a combination of theobromine and theophylline, as well as caffeine.
=== Warfarin === Excessive use of alcohol is known to affect the metabolism of warfarin and can elevate the INR, and thus increase the risk of bleeding. The U.S. Food and Drug Administration (FDA) product insert on warfarin states that alcohol should be avoided. The Cleveland Clinic suggests that when taking warfarin one should not drink more than "one beer, 6 oz of wine, or one shot of alcohol per day".
ErythroMer is a red blood cell substitute in development by KaloCyte, supported with funding by the National Institutes of Health, U.S. Department of Defense, and private investment. Similar to other hemoglobin-based oxygen carriers, the product is stable for several months even when freeze-dried. It can be reconstituted from this lyophilized state in emergencies. This opens up the possibility of eventual stockpiling of ErythroMer, making it easier to supply blood in large amounts to those who need it. The development of this technology was done at Washington University in St. Louis and University of Illinois Urbana-Champaign. Trials have been successful in rats, mice, and rabbits, and human trials are planned. ErythroMer is a reddish blood powder composed of hemoglobin from humans. By coating it with a synthetic polymer, it can sense pH changes, allowing for oxygen pick up in areas where the pH levels are high and disposal where they are low. In the spring of 2024, ErythroMer showed promise in pre-clinical testing. In animal testing, it effectively delivered oxygen and helped revive animals with significant blood loss. In 2025, KaloCyte announced a licensing agreement with Chrysea for ErythroMer production.
Sources: en.wikipedia.org
The Captagon was all destroyed by the new government; "Khattab", a pseudonym of one of the former rebels said "We destroyed and burned it because it's harmful to people. It harms nature and people and humans." The New York Times reported in December 2021 that the Syrian Army's elite 4th Armoured Division, commanded by Maher al-Assad, the brother of Syrian President Bashar al-Assad, oversaw much of the production and distribution of fenethylline, among other drugs. The unit controlled manufacturing facilities, packing plants, and smuggling networks all across Syria, and had started to deal in crystal meth. The division's security bureau, headed by Maj. Gen. Ghassan Bilal, provided protection for factories and along smuggling routes to the port city Latakia and to border crossings with Jordan and Lebanon. Jihad Yazigi, editor of The Syria Report, reported that fenethylline had "probably become Syria's most important source of foreign currency."
Pneumatic tube systems have been used in nuclear chemistry to transport samples during neutron activation analysis. Samples must be moved from the nuclear reactor core, in which they are bombarded with neutrons, to the instrument that measures the resulting radiation. As some of the radioactive isotopes in the sample can have very short half-lives, speed is important. These systems may be automated, with a magazine of sample tubes that are moved into the reactor core in turn for a predetermined time, before being moved to the instrument station and finally to a container for storage and disposal. Until it closed in early 2011, a McDonald's in Edina, Minnesota claimed to be the "World's Only Pneumatic Air Drive-Thru," sending food from their strip-mall location to a drive-through in the middle of a parking lot. Technology editor Quentin Hardy noted renewed interest as of 2015 in transmission of data by pneumatic tube accompanied discussions of digital network security, and he cited research into London's forgotten pneumatic network. Translogic is one of the largest modern healthcare pneumatic tube providers. KUKA is a German manufacturer of industrial robots and factory automation systems. In 2016, the company was acquired by the Chinese appliance manufacturer Midea Group. KUKA acquired Swisslog in 2014 and Translogic in 1999. Related applications include fish cannons which use mechanisms very similar to pneumatic tube systems.
bacteria (e.g. bacteriocin, and many others) fungi (e.g. peptaibols, plectasin, and many others) cnidaria (e.g. hydramacin, aurelin) many from insects and arthropods (e.g. cecropin, attacin, melittin, mastoparan, drosomycin, thioester-containing protein 1) amphibia, frogs (magainin, dermaseptin, aurein, and others) birds (e.g. avian defensins) and mammals (e.g. cathelicidins, alpha- and beta-defensins, regIII peptides) Research has increased in recent years to develop artificially-engineered mimics of antimicrobial peptides such as SNAPPs, in part due to the prohibitive cost of producing naturally-derived AMPs. An example of this is the facially cationic peptide C18G, which was designed from the C-terminal domain of human platelet factor IV. Currently, the most widely used antimicrobial peptide is nisin; being the only FDA approved antimicrobial peptide, it is commonly used as an artificial preservative.
=== Frequency and seriousness of adverse effects === As with all medication, the frequency and seriousness of side-effects varies greatly depending on quantities consumed. In a study about bromazepam's negative effects on psychomotor skills and driving ability, it was noted that 3 mg doses caused minimal impairment. It also appeared that impairment may be tied to methods of testing more so than on the product's intrinsic activity. Moreover, side effects other than drowsiness, dizziness and ataxia seem to be rare and not experienced by more than a few percent of users. The use of other, comparable medication seems to display an identically moderate side effect profile.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.